Viking Therapeutics, Inc. (VKTX) Stock Analysis

Q: What is the VKTX stock price target?

Take-profit $33.99 (+19.3% upside). Prior stop was $27.32.

Q: What are the risks of investing in VKTX?

DATA_ISSUE: analyst_target_implausible (raw $92.33 vs price $28.48 — ratio 3.2×). Rejected, falling back to technical TP.; Quality below floor (1.5 < 4.0); DATA_ISSUE: analyst_target_implausible (raw $92.33 vs price $28.48 — ratio 3.2×). Rejected, falling back to technical TP.; Quality below floor (1.5 < 4.0).

Q: Is VKTX overvalued or undervalued?

Viking Therapeutics, Inc. trades at a P/E of N/A (forward -6.3). TrendMatrix value score: 5.0/10. Overall verdict: Sell.

Q: What do analysts say about VKTX?

25 analysts cover VKTX with a consensus score of 4.2/5. Average price target: $92.

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 1 days ago (May 19, 2026, 11:06 AM ET)

Healthcare · Biotechnology

Viking Therapeutics is a clinical-stage biopharmaceutical company developing VK2735 (GLP-1/GIP dual agonist) for obesity in Phase 3 VANQUISH trials (SC) and Phase 3 initiation planned Q3 2026 (oral), plus VK2809 for NASH/MASH. No products approved; relies on Ligand-licensed... Read more

$28.43+19.3% A.UpsideScore 4.3/10#136 of 157 Biotechnology

QualityF-score2 / 9FCF yield-5.32%

Stop $27.32Target $33.99(resistance)A.R:R 0.0:1

Analyst target$92.33+224.8%18 analysts

$33.99our TP

$28.43price

$92.33mean

$125

Sell if holding. Engine safety override at $28.43: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 21%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.3/10, moderate confidence.

Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 71d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Recent Developments — Viking Therapeutics, Inc.

Latest news

10 Health Care Stocks Whale Activity In Today's Session — benzinga May 12, 2026 neutral
Viking Therapeutics Presents Additional Data From Phase 2 VENTURE-Oral Dosing Trial Evaluating Oral Tablet Formulation O — benzinga May 12, 2026 positive
Stock Market Today: Oil Jumps 5%, S&P 500 Drops As Iran Strikes UAE Port — benzinga May 4, 2026 neutral
Cantor Fitzgerald Maintains Overweight on Viking Therapeutics, Lowers Price Target to $100 — benzinga Apr 30, 2026 positive
Viking Therapeutics Q1 EPS $(1.37) Misses $(1.02) Estimate — benzinga Apr 29, 2026 negative

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards

No bull case signals

Risks

DATA_ISSUE: analyst_target_implausible (raw $92.33 vs price $28.48 — ratio 3.2×). Rejected, falling back to technical TP.

Quality below floor (1.5 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-6.3

Mkt Cap$3.3B

EV/EBITDA—

Profit Mgn0.0%

ROE-70.0%

Rev Growth—

Beta0.71

DividendNone

Rating analysts25

Quality Signals

Piotroski F2/9

Options Flow

P/C0.73neutral

IV68%elevated

Max Pain$20-29.7% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.015%0.75

Quality1.515%0.22

Growth5.015%0.75

Momentum1.310%0.13

Sentiment8.110%0.81

Insider Activity5.010%0.50

Peer Rank3.910%0.39

Technical Setup7.65%0.38

Risk Profile3.45%0.17

Catalyst3.65%0.18

Overall (Σ contributions)4.29

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd

0.0

Volume

0.0

Obv

1.0

Ma Position

2.2

Rsi

3.5

Volume distribution (falling OBV)Below 200-MA but MA still rising (+1.1%/30d) — pullback in uptrend, not confirmed weakness

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

2.2

Moat

3.8

Current Ratio

7.3

Cash-burning (FCF negative)No competitive moatWeak Piotroski F-Score: 2/9Quality concerns

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Erm

5.0

Earnings Timing

5.0

News Activity

8.0

Earnings concerns: 0B/4M

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.7

Value Rank

5.0

Growth Rank

5.0

GatesMomentum 1.3<4.5A.R:R UPSIDE_EXHAUSTED (upside=0.0%)Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 71d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive

RSI

36 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $28.16Resistance $34.68

Price Targets

$27

$34

A.Upside+19.6%

A.R:R0.0:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! DATA_ISSUE: analyst_target_implausible (raw $92.33 vs price $28.48 — ratio 3.2×). Rejected, falling back to technical TP.

! Quality below floor (1.5 < 4.0)

! Momentum score 1.3/10 — below 4.5 minimum

Earnings

0/4 beats

Next Earnings2026-07-29 (71d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is VKTX stock a buy right now?

Sell if holding. Engine safety override at $28.43: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: High short interest: 21%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $27.32. Score 4.3/10, moderate confidence.

What is the VKTX stock price target?

Take-profit target: $33.99 (+19.3% upside). Prior stop was $27.32. Stop-loss: $27.32.

What are the risks of investing in VKTX?

DATA_ISSUE: analyst_target_implausible (raw $92.33 vs price $28.48 — ratio 3.2×). Rejected, falling back to technical TP.; Quality below floor (1.5 < 4.0).

Is VKTX overvalued or undervalued?

Viking Therapeutics, Inc. trades at a P/E of N/A (forward -6.3). TrendMatrix value score: 5.0/10. Verdict: Sell.

What do analysts say about VKTX?

25 analysts cover VKTX with a consensus score of 4.2/5. Average price target: $92.

What does Viking Therapeutics, Inc. do?Viking Therapeutics is a clinical-stage biopharmaceutical company developing VK2735 (GLP-1/GIP dual agonist) for...